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background: Clomifene citrate (CC) is accepted as the ﬁrst-line method for ovulation induction (OI) in patients with polycystic ovary syn-
drome (PCOS) associatedwith infertility owing to anovulation. Low-dose FSHhas been reserved forwomen failing to conceivewithCC. In this RCT,
we tested thehypothesis that pregnancy rate (PR) and livebirth rates (LBR) arehigherafterOIwith low-dose FSH thanwithCCas ﬁrst-line treatment.
methods: Infertile women (,40 years old) with PCOS-related anovulation, without priorOI treatment, attending 10 centres in Europe/South
America were randomized to OI with either CC (50–150 mg/day for 5 days) or FSH (starting dose 50 IU) for up to three treatment cycles. The
primary outcome was clinical PR.
results: Patients (n ¼ 302) were randomized toOI with FSH (n ¼ 132women; 288 cycles) or CC (n ¼ 123; 310 cycles). Per protocol analysis
revealed that reproductive outcomewas superior after OI with FSH than with CC with respect to PR per ﬁrst cycle [30 versus 14.6%, respectively,
95% conﬁdence interval (CI) 5.3–25.8, P ¼ 0.003], PR per woman, (58 versus 44% of women, 95% CI 1.5–25.8, P ¼ 0.03), LBR per woman (52
versus 39%, 95%CI 0.4–24.6, P ¼ 0.04), cumulative PR (52.1 versus 41.2%, P ¼ 0.021) and cumulative LBR (47.4 versus 36.9%, P ¼ 0.031), within
three cycles of OI.
conclusions: Pregnancies and live births are achievedmore effectively and faster afterOIwith low-dose FSH thanwithCC. This result has to
be balanced by convenience and cost in favour of CC. FSHmay be an appropriate ﬁrst-line treatment for somewomen with PCOS and anovulatory
infertility, particularly older patients.
clinical trials registration: ISRCTN41865643.
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Introduction
Polycystic ovary syndrome (PCOS) is the most prevalent female endocri-
nopathy affecting at least 7% of all women in the fertile age group (Kousta
et al., 1997). The symptomsofPCOS include irregularorabsentovulation,
hyperandrogenismmanifesting as hirsutism and persistent acne, and char-
acteristic changes in ovarian morphology. The syndrome is often
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accompanied by abdominal obesity and insulin resistance and, as such, is
frequently associatedwith themetabolic syndrome. PCOS is diagnosed in
75% ofwomenwith anovulatory infertility (Kousta et al., 1997): successful
treatment by ovulation induction (OI) will result in the delivery of a single
healthy baby avoiding the complications ofmultiple pregnancy and ovarian
hyperstimulation syndrome (OHSS).
For almost 50 years, the undisputed ﬁrst-line medication for OI in
PCOS has been clomifene citrate (CC). CC is a simple, cheap and
effective method to induce ovulation with minimal side-effects.
Acting as an estrogen receptor antagonist in the hypothalamus and
anterior pituitary, thus increasing the secretion of FSH, CC induces
ovulation in 75–80% of patients but pregnancy is achieved in only
35–40% (Homburg, 2005). The discrepancy between ovulation and
pregnancy rates is thought to be related mainly to the anti-estrogenic
effect of CC on cervical function and on endometrial receptivity.
Increased LH secretion induced by CC, which does not occur with
FSH administration, may also reduce the likelihood of conception
(Hamilton-Fairley and Franks, 1990).
When CC resistance (failure to ovulate with maximal doses) or CC
failure (failure to conceive despite ovulation in six or more cycles of
treatment) occurs, the accepted second-line of treatment is direct
ovarian stimulation and OI with injectable FSH. In the earlier days of
gonadotrophin administration, this was fraught with the complications
of multiple pregnancy and OHSS which could even be life-threatening
(Hamilton-Fairley and Franks, 1990) owing to the high sensitivity of poly-
cystic ovaries to FSH. Fortunately, these complications have been largely
overcome following the introduction of low-dose protocols for the
administration of FSH, which achieve mono-ovulation in 70% of cycles
(Polson et al., 1987; Homburg and Howles, 1999). This has almost
completely eliminated the prevalence of severe OHSS and has
lowered the incidence of multiple pregnancy from 34 to ,6%
(Hamilton-Fairley and Franks, 1990; Homburg and Howles, 1999).
These clear beneﬁts of the low-dose FSH protocol as a second-line
therapy suggested the possibility of using it as a ﬁrst-line approach for
OI in PCOS, which might result in an increased singleton pregnancy
rate and shorter treatment to pregnancy interval. The aim of this
RCT was to test the hypothesis that the (cumulative) pregnancy
rate (PR) and live birth rates (LBR) in OI are higher with low-dose
FSH than with CC as a ﬁrst-line treatment.
Materials and Methods
A prospective, randomized, multicentre, multinational, controlled trial in
10 centres throughout Europe and South America. This study was
reported according to the CONSORT criteria for RCTs comparing
medical treatment in two different arms.
Subjects were ,40 years old. There were no weight or BMI restric-
tions. Tubo-peritoneal evaluation was performed only in subjects with
a previous history of pregnancy resulting in a spontaneous abortion, a
previous history of gynaecological or abdominal surgical intervention or
pelvic inﬂammatory disease. Those admitted to the study all had a
normal uterine cavity and tubal patency demonstrated by radiological (hys-
terosalpingogram), laparoscopic or ultrasonic means before entering the
study. Male partners all had a normal semen analysis conforming to
World Health Organization criteria (World Health Organization, 1999).
The study was conducted from August 2005 to March 2009.
A power calculation, using Russ Lenth’s power and sample size compar-
ing two proportions (Lenth, 2006–2009) demonstrated that 150 subjects
were required in each arm to achieve a relative increase in PR of 50% from
35 to 52.5% with 80% power, a signiﬁcance level of 0.05 and allowing for a
total of 50 drop outs from the study.
Treatment-naı¨ve women (n ¼ 302) with anovulatory or oligo-ovulatory
infertility associated with PCOS (diagnosed according to the Rotterdam
European Society of Human Reproduction and Embryology/American
Society for Reproductive Medicine criteria, 2004) were randomized by
computer-generated randomization in sealed opaque envelopes, to
receive three cycles of either CC or FSH. Randomization was stratiﬁed by
centre in blocks of 20 inclusions per centre. The starting dose of CC was
50 mg/day (oral) for 5 days from Day 4 of a spontaneous or
progestin-induced menstruation, rising by 50 mg/day up to 150 mg in
subsequent cycles if ovulation was not achieved. Recombinant human
FSH (Puregon, Schering-Plough, Houten, The Netherlands) was given s.c.
in a low-dose protocol starting with 50 IU on cycle day 4, with weekly incre-
ments of 25 IU as necessary to induce a follicular response (Leader, 2006).
Treatment cycles were monitored by ultrasound examination of follicle
number and size and endometrial thickness starting on Day 11 of the cycle
for both CC and FSH cycles. Repeat examination was performed every 1–
3 days as clinically indicated until the criterion for hCG administration
........................................................................................
Table I Baseline demographic and clinical
characteristics of patients in a prospective, randomized
multinational study of CC versus low-dose FSH for the
ﬁrst-line treatment of infertile women with
anovulation associated with PCOS.
CC
(n5 143)
FSH
(n 5 159)
Age (years) 29.4 (4.0) 29.8 (3.8)
BMI (kg/m2) 25.7 (6.0) 25.1 (5.2)
Waist circumference (cm) 91.1 (13.9) 91.5 (11.8)
Duration of infertility (years) 2.1 (1.8) 2.1 (1.9)
Primary infertility 107 (75%) 124 (78%)
Secondary infertility 36 (25%) 35 (22%)
*Clinical or biochemical hyperandrogenism 111 (78%) 102 (64%)
Polycystic ovaries on ultrasound 143 (100%) 159 (100%)
Duration of average cycle
,28 days 2 (1%) 3 (2%)
28–35 days 6 (4%) 10 (6%)
36–90 days 56 (39%) 72 (45%)
91–180 days 40 (28%) 36 (23%)
.180 days 38 (27%) 34 (21%)
LH (IU/l) 10.1 (4.4) 9.8 (5.9)
FSH (IU/l) 5.8 (1.4) 5.5 (1.7)
Testosterone (nmol/l) 2.1 (0.9) 2.1 (0.9)
Androstenedione (nmol/l) 8.7 (3.3) 8.4 (3.5)
**DHEAS (mmol/l) 5.4 (2.4) 4.4 (2.2)
SHBG (nmol/l) 52.5 (28.9) 50.6 (24.6)
17-OH progesterone (nmol/l) 3.8 (1.9) 3.5 (1.5)
Fasting glucose (mg/dl) 82.7 (16.7) 81.7 (20.6)
Fasting insulin (IU/l) 8.6 (5.6) 8.3 (5.9)
DHEAS, dehydroepiandrosterone sulphate; SHBG, sex hormone-binding globulin.
Data are mean (SD) or n (%).
*P, 0.01.
**P, 0.04, multivariate analysis CC versus FSH.
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(10 000 IU i.m.) was reached (at least one follicle ≥17 mm diameter).
hCG was withheld if three or more follicles of .15 mm diameter were
seen on ultrasound. Intercourse was advised on the day of hCG and the
following day. Clinical pregnancy was deﬁned as a pregnancy diagnosed
by ultrasonographic visualization of one or more gestational sacs with at
least one foetus at 6–7 weeks gestation and this pregnancy was
deemed as ongoing pregnancy if it continued for more than 20 completed
weeks of gestation. A miscarriage was deﬁned as the spontaneous loss of a
clinical pregnancy before 20 completed weeks of gestation and a multiple
pregnancy as one in which there was more than one foetus. A live birth
was deﬁned as the birth of a viable infant, reported on a clinical research
form transmitted to the co-ordinating centre.
Each participating centre received appropriate ethical and other regula-
tory committee approvals (registered trial ISRCTN41865643). An
informed consent form was signed by every participant in the study.
All biochemical analyses were performed with commercially avail-
able kits. LH and FSH were measured using a two-step immunoassay,
total testosterone with a standard immunoassay, androstendione and
sex hormone-binding globulin with an enzyme immunoassay, dehy-
droepiandrosterone sulphate (DHEAS) and 17-hydroxy progesterone
with a delayed one-step immunoassay, fasting glucose with hexoki-
nase/glucose-6-phosphate dehydrogenase methodology and insulin
by immunoradiometric assay.
Statistical analyses
Descriptive statistical analyses were performed using x2 and t-tests. Both
per protocol analysis and intention-to-treat analysis were carried out. To
calculate cumulative PR and LBR, we used the Kaplan–Meier survival
analysis. An important advantage of the Kaplan–Meier curve is that the
method can take into account ‘censored’ data, which are losses caused
by drop outs from the study before the ﬁnal outcome (pregnancy) is
observed (Daya, 2005). The log-rank test was used to test the probability
that there was a difference in survival scores between the CC and FSH
groups. Statistical analysis was performed using the Statistical Package
for the Social Sciences 15.0 software for Windows (SPSS Inc., Chicago,
IL, USA). Statistical signiﬁcance was set at P, 0.05.
Results
Of 302 subjects randomized, 143 received CC (340 cycles) and 159
received low-dose FSH (326 cycles). The only demographic or clinical
differences between the randomized groups, conﬁrmed by multivari-
ate analysis, were a higher prevalence of clinical hyperandrogenism
(P, 0.01) and higher serum DHEAS concentrations (P, 0.04) in
the CC group (Table I). In the CC group, 20 patients did not complete
the full study (5 inter-cycle and 1 chemical pregnancy and 14 for
Figure 1 Proﬁle of prospective, randomized multinational study of CC versus low-dose FSH for the ﬁrst-line treatment of infertile women with
anovulation associated with PCOS. FSH, low-dose FSH.
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personal reasons) compared with 27 in the FSH group (4 inter-cycle
and 3 chemical pregnancies, 19 for personal reasons and 1 following
a cycle cancelled because of overstimulation) leaving 123 patients in
the CC group and 132 patients in the FSH group evaluable for analysis
(310 cycles CC, 288 cycles FSH) (Fig. 1). Thus, only one subject with-
drew from the study owing to a treatment-related effect (overstimu-
lation). For analysis, all started treatment cycles were considered.
Intention-to-treat analysis
The intention-to-treat analysis revealed that the PR per cycle was
higher after OI with FSH (23.3%) than after OI with CC (15.9%)
[95% conﬁdence interval (CI) 1.3–14, P ¼ 0.016], and that there
was a similar proportion of women achieving a clinical pregnancy
(80/159; 50.3 versus 59/143 or 41.3%, 95% CI 22.1 to 20.3, P ¼
0.1) or a live birth (72/159 or 45.3 versus 53/143 or 37%, 95%
CI 2.8 to 19.3, P ¼ 0.12).
Per protocol analysis
Of the women receiving CC, 63% ovulated on the minimum dose of
50 mg a day resulting in 39 of the 54 pregnancies (72.2%) achieved
with CC. Eight women (6.5%) were CC resistant, failing to ovulate
on 150 mg/day. Treatment was cancelled in 19 (6.6%) of the 288
cycles of low-dose FSH treatment because of overstimulation and
so hCG was withheld to prevent multiple pregnancy and ovarian
hyperstimulation. There were no such cases of overstimulation in
the CC group.
When compared with OI with CC, OI with FSH was associated
with a higher proportion of women achieving a clinical pregnancy
(58 or 76/132 versus 44% or 54/123, 95% CI 1.5–25.8, P ¼ 0.03)
or a live birth (52 or 68/132 versus 39% or 48/123, 95% CI 0.4–
24.6, P ¼ 0.04) (Table II). When compared with OI with CC, OI
with FSH was associated with a higher PR per cycle (26.4 versus
17.4%, 95% CI 2.4–15.6, P ¼ 0.008), but with a similar multiple PR,
ﬁrst trimester miscarriage rate and ectopic PR (Table II).
Clinical pregnancies in the CC group were achieved fairly evenly
over the three cycles (33, 41 and 26% of the pregnancies, respective-
ly), whereas those from FSH were mainly achieved in cycle 1 (52.6%)
with a further 35.5% in cycle 2. The PR after the ﬁrst cycle of treat-
ment was twice as high after OI with FSH (30%) than after OI with
CC (14.6%, 95% CI 5.3–25.8, P ¼ 0.003). The PR after the ﬁrst
two cycles of treatment was also higher after OI with FSH (50.7%)
than after OI with CC (32.5%, P ¼ 0.003).
By survival analysis, using the Kaplan–Meier and log-rank test, the
cumulative clinical PR after three cycles was 41.2% for the CC
group compared with 52.1% for the FSH group (P ¼ 0.021). The
cumulative LBR after three cycles was 36.9% for the CC group com-
pared with 47.4% for the FSH group (P ¼ 0.031; Fig. 2).
Cost of visits
The monetary costs of follicle tracking and administrative were the
same for both treatments (data not shown). The number of ultra-
sound monitoring visits per cycle was 3.3 for CC and 4.1 for FSH,
the number of visits per live birth therefore was 12.3% greater with
CC than FSH.
Overall, on per protocol analysis, there was both a relative and an
absolute advantage in reproductive outcome after OI with low-dose
FSH when compared with OI with CC with respect to clinical PR
after the ﬁrst cycle (100 and 13%, respectively), PR per cycle over
the three cycles (77 and 13%), cumulative PR within three cycles
(27 and 11%) and cumulative LBR within three cycles (27 and 10%).
Discussion
Our study demonstrated that in treatment-naive patients with PCOS,
the reproductive outcome after OI with low-dose FSH was signiﬁcant-
ly better than after OI with CC, with respect to clinical PR and LBR
per (ﬁrst) cycle, cumulative clinical PR and LBR over three cycles
and time to pregnancy. These results are in line with the trend
observed in another similar study but which did not reach signiﬁcance
because of the small numbers involved (n ¼ 38 in each group) (Lopez
et al., 2004).
Although from the patient perspective CC is more convenient (oral
intake) and cheaper than low-dose FSH, this relative advantage for CC
is reduced as current guidelines in most countries now recommend
the same intensity of monitoring with ultrasound for CC cycles as
for low-dose FSH treatment. Furthermore, 7–15% of subjects do
not ovulate with maximal doses of CC and 15–50% of those who
ovulate demonstrate a suppressed thin endometrium which consider-
ably reduces the chance of pregnancy (Gonen and Casper, 1990;
Homburg, 2005). In contrast, OI with low-dose FSH is not associated
with an anti-endometrial effect and only rarely associated with ovula-
tion failure (Homburg and Howles, 1999).
While our study conﬁrmed our hypothesis that OI with low-dose
FSH results in a high PR and LBR, the reproductive outcome after
OI with CC was better than expected (high PR and LBR) and surpris-
ingly was associated with a complete absence of multiple pregnancies
(Homburg, 2005). We hypothesize that these positive outcomes after
OI with CC can be explained by the low starting dose (50 mg/day),
the consistent use of ultrasound monitoring, patient management in
........................................................................................
Table II Results (per-protocol) comparing treatment
with clomifene and low-dose FSH.
CC FSH P-value
Number of patients randomized 143 159
Number of patients per protocol 123 132
Cycles 310 288
Clinical pregnancies (per patient) 54 (44%) 76 (58%) 0.03
Ongoing pregnancies (per patient) 48 (39%) 68 (52%) 0.04
Clinical pregnancies (per cycle) 54 (17.4%) 76 (26.4%) 0.008
Ectopic pregnancies 1 1
Miscarriage rate per pregnancya 5 (9.2%) 7 (9.2%)
Multiple pregnancies (twins only) 0 2 (3.4%)
Cumulative pregnancy rate
Cycle 1 12.9% 25.6%
Cycle 2 29.3% 44.8%
Cycle 3 41.2% 52.1% 0.02
Data are n (%), x2 and t-tests (two-sided) used for simple comparisons and Kaplan–
Meier survival analysis for cumulative pregnancy rates
aIn ﬁrst trimester.
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specialized OI settings and accurate timing of sexual intercourse. The
criteria for the timing of hCG administration in both arms were the
same. Although it has been common practice to administer hCG in
CC cycles at a later stage of follicular growth than in FSH cycles,
there is little evidence to support this practice which has also been
recently disputed (Farhi et al., 2010). Further, the high PRs following
CC in this study suggest that using the same criteria for hCG admin-
istration for both arms did not inﬂuence results.
Although differences in cost and convenience may limit the choice
of FSH as ﬁrst-line treatment in some settings, our results may
justify OI with low-dose FSH as a ﬁrst line of treatment in other set-
tings where this is ﬁnancially possible and where there is access to the
required level of monitoring expertise. While we agree that the cost of
recombinant human FSH is much higher than CC, this cost difference
is offset by a number of factors: (i) The likelihood of pregnancy after
the ﬁrst cycle of OI with low-dose FSH is twice as high than after
OI with CC; (ii) Follicle tracking and administrative costs are the
same for both treatments—the number of visits per live birth there-
fore is greater with CC than FSH and (iii) The psychological burden
on women taking CC who undergo 6–12 cycles without conceiving
before progressing to low-dose FSH therapy should also be
considered.
In conclusion, our study has, for the ﬁrst time, shown that repro-
ductive outcome is superior after OI with low-dose FSH when com-
pared with OI with CC. These data may be utilized when balancing
the pros and cons of initiating OI with low-dose FSH rather than OI
with CC for women with PCOS-associated anovulatory infertility.
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